Cancer, colorectal and others: Aspirin for primary or secondary prevention
DISEASE INTERVENTION COMPARISON RESULTS
Lancet. 2011 Jan 1;377(9759):31-41. Epub 2010 Dec 6 Meta-Analysis
IN cancer, all types, gastrointestinal cancers The Use of
aspirin, 75 mg daily or more, for more than 5 years
As Prevention, Primary
Is better Than
placebo
To reduce death due to all cancers (0.79) when treatment maintained for more than 5 years, specially for gastrointestinal cancers (OR 0.46) but also for brain, lung and prostate cancers.
Lancet. 2010 Nov 20;376(9754):1741-50 Meta-Analysis
IN cancer, colorectal The Use of
aspirin dose, 75 mg daily or more, for more than 5 years
As Prevention, Primary
Is better Than
placebo
To reduce the 20-year risk of colon cancer incidence (HR 0.76) and mortality (HR 0.65), specially of proximal colon cancer.
N Engl J Med. 2003 Mar 6;348(10):883-90 Randomized Controlled Trial, Multicenter Study
IN cancer, colorectal The Use of
aspirin (325 mg daily)
As Prevention, Secondary
Is better Than
placebo
To prevent new colorectal adenomes in colonoscopy, at 12,8 months (17% in intv VS 27% in ctrl)